Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal trial for nPulse AF catheter system
Bitget2026/10/07 11:00Pulse Biosciences reached its enrollment target in the NANOPULSE-AF IDE pivotal study of its nPulse cardiac catheter system for atrial fibrillation. The trial enrolled 164 evaluable patients across 15 US clinical sites, moving the program into patient follow-up and study completion. No clinical results were presented in the announcement; results are expected in the future once follow-up concludes. Management highlighted faster-than-planned enrollment, supporting timelines for potential regulatory and commercialization milestones without disclosing efficacy outcomes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007497622) on October 07, 2026, and is solely responsible for the information contained therein.
- Pulse Biosciences reached its enrollment target in the NANOPULSE-AF IDE pivotal study of its nPulse cardiac catheter system for atrial fibrillation.
- The trial enrolled 164 evaluable patients across 15 US clinical sites, moving the program into patient follow-up and study completion.
- No clinical results were presented in the announcement; results are expected in the future once follow-up concludes.
- Management highlighted faster-than-planned enrollment, supporting timelines for potential regulatory and commercialization milestones without disclosing efficacy outcomes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Crypto prices
More
